论文部分内容阅读
非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)约占恶性淋巴瘤发病的90%,分为B细胞和T细胞两大类,其各个亚型在组织病理学、临床表现及预后都不尽相同。目前临床上广泛应用的利妥昔单抗联合化疗可明显改善多种B-NHL的预后,但仍有约1/3晚期B-NHL患者会由于多种原因导致初次治疗无效或短期有效进而复发与进展。近年来,细胞信号通路中的关键分子在淋巴肿瘤治疗中的作用日益受到重视。研究发现多种特异性信号通路异常表达与淋巴瘤细胞的恶性增殖相关,针对这些信号通路所开发出的靶向药物有可能成为NHL新的治疗方向。本文就与淋巴瘤发生相关的信号转导通路及对应靶向药物的临床应用状况做以下综述。
Non-Hodgkin’s lymphoma (NHL) accounts for about 90% of the incidence of malignant lymphoma, divided into two major types of B cells and T cells, each of its subtypes in histopathology, clinical manifestations and prognosis are not Do the same. Currently widely used in clinical rituximab combined with chemotherapy can significantly improve the prognosis of a variety of B-NHL, but there are still about 1/3 of patients with advanced B-NHL for many reasons lead to ineffective initial treatment or short-term effective and then relapse With progress. In recent years, the role of key molecules in cell signaling pathways in the treatment of lymphatic neoplasia has received increasing attention. The study found that the abnormal expression of multiple specific signal transduction pathways and malignant proliferation of lymphoma cells related to the development of these signaling pathways targeted drugs may become NHL new treatment direction. This article reviews the status of clinical applications of the signal transduction pathways associated with lymphoma occurrence and the corresponding targeted drugs.